We hypothesized that VHL missense mutations occurring in the p53 binding domain of pVHL lead to deficient p53 transactivation and/or promote HIF1α and HIF2α accumulation, thus impacting tumor behavior and response to treatment. The gene discussed is TP53; the disease is neoplasm.